Joseph Skalski, MD
Pulmonary Disease · Rochester, MNNPI 1548499759
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,191 of the $8,191 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Sanofi. Among pulmonary disease clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1 payment — averaging $8191.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$8K
Across 170 payments — averaging $652.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$69K
- Sanofi US Services Inc.$38K
- Amgen$5K
What the payments were for
- Consulting fees$8,191100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $8,191 |
How this compares
$8,191 in reported general payments places this provider in the 90th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $322,924 |
| Dupixent PenDupilumab | 50 | $189,882 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $72,041 |
| Breo ElliptaFluticasone/Vilanterol | 92 | $52,377 |
| NucalaMepolizumab | 14 | $50,511 |
| TezspireTezepelumab-Ekko | 11 | $49,507 |
| Spiriva RespimatTiotropium Bromide | 73 | $38,478 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 74 | $38,444 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $27,923 |
| Incruse ElliptaUmeclidinium Bromide | 55 | $20,665 |
| Advair HfaFluticasone Propion/Salmeterol | 45 | $19,510 |
| Spiriva HandihalerTiotropium Bromide | 11 | $15,850 |
| DuleraMometasone/Formoterol | 31 | $15,164 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $14,344 |
| Arnuity ElliptaFluticasone Furoate | 37 | $12,001 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Rochester
- Hilary DubrockRochester$102K
- Ulrich SpecksRochester$77K
- Jagdeep BijwadiaRochester$54K
- Teng MouaRochester$47K
- Timothy AksamitRochester$26K
- Michael KrowkaRochester$25K
- Kaiser LimRochester$18K
- Robert VassalloRochester$18K
- Eva Carmona PorqueraRochester$17K
- Tobias PeikertRochester$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.